ONTOLOGY REPORT - ANNOTATIONS
| Term: | gefitinib |
|
| Accession: | CHEBI:49668
|
browse the term
|
| Definition: | A quinazoline that has formula C22H24ClFN4O3. |
| Synonyms: | exact_synonym: | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine |
| | related_synonym: | 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; C22H24ClFN4O3; COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1; InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27); InChIKey=XGALLCVXEZPNRQ-UHFFFAOYSA-N; Iressa; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine; ZD 1839 |
| | alt_id: | CHEBI:38917; CHEBI:49667 |
| | xref_casrn: | 184475-35-2 |
| | xref: | ChEMBL:188232 "ChEMBL COMPOUND"; ChemIDplus:184475-35-2 "CAS Registry Number"; DrugBank:DB00317 "DrugBank" |
| | xref_mesh: | MESH:C419708 |
| | xref: | PDBeChem:IRE "PDBeChem"; Wikipedia:Gefitinib "Wikipedia" |
|
|
gefitinib
|
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
multiple interactions |
ISO |
4 |
87,502,584 |
87,560,017 |
RGD:6480464 |
CTD |
| G |
Adora1 |
adenosine A1 receptor |
|
decreases expression |
ISO |
13 |
47,160,292 |
47,192,804 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Areg |
amphiregulin |
|
affects response to substance |
ISO |
14 |
18,466,313 |
18,475,571 |
RGD:6480464 |
CTD |
| G |
Areg |
amphiregulin |
|
decreases response to substance |
ISO |
14 |
18,466,313 |
18,475,571 |
RGD:6480464 |
CTD |
| G |
Areg |
amphiregulin |
|
multiple interactions |
ISO |
14 |
18,466,313 |
18,475,571 |
RGD:6480464 |
CTD |
| G |
Areg |
amphiregulin |
|
decreases response to substance |
ISO |
14 |
18,466,313 |
18,475,571 |
RGD:6480464 |
CTD |
| G |
Atg5 |
autophagy related 5 |
|
increases expression |
ISO |
20 |
48,273,977 |
48,366,743 |
RGD:6480464 |
CTD |
| G |
Atg7 |
autophagy related 7 |
|
increases expression |
ISO |
4 |
150,814,706 |
150,992,704 |
RGD:6480464 |
CTD |
| G |
Aurka |
aurora kinase A |
|
decreases response to substance |
ISO |
3 |
163,270,479 |
163,284,506 |
RGD:6480464 |
CTD |
| G |
Aurka |
aurora kinase A |
|
multiple interactions |
ISO |
3 |
163,270,479 |
163,284,506 |
RGD:6480464 |
CTD |
| G |
Aven |
apoptosis, caspase activation inhibitor |
|
affects response to substance |
ISO |
3 |
98,404,029 |
98,475,755 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases response to substance |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cav1 |
caveolin 1, caveolae protein |
|
increases expression |
ISO |
4 |
42,956,102 |
42,989,057 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd3 |
cyclin D3 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
multiple interactions |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
decreases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
increases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
increases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
|
increases expression |
ISO |
5 |
108,939,669 |
108,945,293 |
RGD:6480464 |
CTD |
| G |
Cgrrf1 |
cell growth regulator with ring finger domain 1 |
|
increases expression |
ISO |
15 |
22,683,387 |
22,703,833 |
RGD:6480464 |
CTD |
| G |
Cldn2 |
claudin 2 |
|
multiple interactions |
ISO |
X |
127,538,685 |
127,549,019 |
RGD:6480464 |
CTD |
| G |
Col4a3bp |
collagen, type IV, alpha 3 (Goodpasture antigen) binding protein |
|
affects response to substance |
ISO |
2 |
27,012,330 |
27,117,057 |
RGD:6480464 |
CTD |
| G |
Coro1c |
coronin, actin binding protein 1C |
|
affects response to substance |
ISO |
12 |
43,747,188 |
43,819,356 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
|
decreases expression |
ISO |
1 |
82,191,741 |
82,204,629 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
affects metabolic processing |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Dusp3 |
dual specificity phosphatase 3 |
|
affects response to substance |
ISO |
10 |
91,031,206 |
91,044,858 |
RGD:6480464 |
CTD |
| G |
Dusp9 |
dual specificity phosphatase 9 |
|
decreases expression |
ISO |
X |
159,538,012 |
159,541,937 |
RGD:6480464 |
CTD |
| G |
E2f1 |
E2F transcription factor 1 |
|
decreases expression |
ISO |
3 |
145,032,489 |
145,043,729 |
RGD:6480464 |
CTD |
| G |
E2f1 |
E2F transcription factor 1 |
|
decreases expression |
ISO |
3 |
145,032,489 |
145,043,729 |
RGD:6480464 |
CTD |
| G |
E2f1 |
E2F transcription factor 1 |
|
decreases expression |
ISO |
3 |
145,032,489 |
145,043,729 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
multiple interactions |
ISO |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
increases response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
increases response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
increases response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases activity |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases expression |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases expression |
EXP |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
EXP |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
increases response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases activity |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects response to substance |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Epor |
erythropoietin receptor |
|
increases expression |
ISO |
8 |
21,061,310 |
21,065,886 |
RGD:6480464 |
CTD |
| G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
|
increases expression |
ISO |
5 |
130,639,805 |
130,739,014 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
decreases phosphorylation |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Ercc1 |
excision repair cross-complementing rodent repair deficiency, complementation group 1 |
|
multiple interactions |
ISO |
1 |
78,711,249 |
78,722,474 |
RGD:6480464 |
CTD |
| G |
Ercc1 |
excision repair cross-complementing rodent repair deficiency, complementation group 1 |
|
affects response to substance |
ISO |
1 |
78,711,249 |
78,722,474 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
decreases phosphorylation |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases expression |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Fgf6 |
fibroblast growth factor 6 |
|
increases expression |
ISO |
4 |
163,403,896 |
163,412,431 |
RGD:6480464 |
CTD |
| G |
Foxo3 |
forkhead box O3 |
|
increases response to substance |
ISO |
20 |
46,171,784 |
46,262,818 |
RGD:6480464 |
CTD |
| G |
Foxo3 |
forkhead box O3 |
|
multiple interactions |
ISO |
20 |
46,171,784 |
46,262,818 |
RGD:6480464 |
CTD |
| G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
|
increases expression |
ISO |
4 |
96,649,941 |
96,652,243 |
RGD:6480464 |
CTD |
| G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
|
decreases expression |
ISO |
17 |
19,230,896 |
19,232,641 |
RGD:6480464 |
CTD |
| G |
Gars |
glycyl-tRNA synthetase |
|
increases expression |
ISO |
4 |
83,718,584 |
83,759,591 |
RGD:6480464 |
CTD |
| G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
|
affects response to substance |
ISO |
8 |
82,724,429 |
82,762,848 |
RGD:6480464 |
CTD |
| G |
Gnb2 |
guanine nucleotide binding protein (G protein), beta polypeptide 2 |
|
decreases expression |
ISO |
12 |
19,597,312 |
19,602,329 |
RGD:6480464 |
CTD |
| G |
Gnmt |
glycine N-methyltransferase |
|
multiple interactions |
ISO |
9 |
10,127,092 |
10,130,444 |
RGD:6480464 |
CTD |
| G |
Gucy2d |
guanylate cyclase 2D, membrane (retina-specific) |
|
decreases expression |
ISO |
10 |
56,012,236 |
56,027,290 |
RGD:6480464 |
CTD |
| G |
Hbegf |
heparin-binding EGF-like growth factor |
|
multiple interactions |
ISO |
18 |
29,143,567 |
29,153,944 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
multiple interactions |
ISO |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
increases phosphorylation |
ISO |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Itgav |
integrin, alpha V |
|
multiple interactions |
ISO |
3 |
66,953,403 |
67,029,774 |
RGD:6480464 |
CTD |
| G |
Itgb1 |
integrin, beta 1 |
|
multiple interactions |
ISO |
19 |
58,600,095 |
58,647,531 |
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
affects response to substance |
ISO |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Lepr |
leptin receptor |
|
decreases expression |
ISO |
5 |
122,320,075 |
122,503,449 |
RGD:6480464 |
CTD |
| G |
Lgals9 |
lectin, galactoside-binding, soluble, 9 |
|
multiple interactions |
ISO |
10 |
65,129,006 |
65,152,052 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases expression |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
decreases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
decreases expression |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases phosphorylation |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mdk |
midkine |
|
multiple interactions |
ISO |
3 |
76,309,988 |
76,311,345 |
RGD:6480464 |
CTD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
decreases expression |
ISO |
8 |
115,616,396 |
115,653,471 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mtor |
mechanistic target of rapamycin (serine/threonine kinase) |
|
decreases phosphorylation |
ISO |
5 |
165,531,402 |
165,640,899 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
decreases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Ndufaf4 |
NADH dehydrogenase (ubiquinone) complex I, assembly factor 4 |
|
multiple interactions |
ISO |
5 |
39,939,787 |
39,944,959 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
decreases expression |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nptx2 |
neuronal pentraxin II |
|
decreases expression |
ISO |
12 |
10,359,406 |
10,370,315 |
RGD:6480464 |
CTD |
| G |
Nrl |
neural retina leucine zipper |
|
decreases expression |
ISO |
15 |
33,649,927 |
33,656,045 |
RGD:6480464 |
CTD |
| G |
Olr93 |
olfactory receptor 93 |
|
multiple interactions |
ISO |
1 |
161,092,784 |
161,093,728 |
RGD:6480464 |
CTD |
| G |
Osmr |
oncostatin M receptor |
|
affects response to substance |
ISO |
2 |
56,080,700 |
56,121,463 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pecam1 |
platelet/endothelial cell adhesion molecule 1 |
|
multiple interactions |
ISO |
10 |
96,056,220 |
96,057,232 |
RGD:6480464 |
CTD |
| G |
Phlda2 |
pleckstrin homology-like domain, family A, member 2 |
|
affects response to substance |
ISO |
1 |
203,878,093 |
203,879,038 |
RGD:6480464 |
CTD |
| G |
Plbd1 |
phospholipase B domain containing 1 |
|
affects response to substance |
ISO |
4 |
173,611,465 |
173,667,759 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Qsox1 |
quiescin Q6 sulfhydryl oxidase 1 |
|
increases expression |
ISO |
13 |
70,739,793 |
70,777,526 |
RGD:6480464 |
CTD |
| G |
Rbm7 |
RNA binding motif protein 7 |
|
affects response to substance |
ISO |
8 |
51,769,353 |
51,774,447 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
decreases response to substance |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rpa1 |
replication protein A1 |
|
increases expression |
ISO |
10 |
62,613,169 |
62,656,565 |
RGD:6480464 |
CTD |
| G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
|
decreases phosphorylation |
ISO |
10 |
76,657,024 |
76,698,088 |
RGD:6480464 |
CTD |
| G |
Rrm1-ps1 |
ribonucleotide reductase M1, pseudogene 1 |
|
affects response to substance |
ISO |
14 |
77,408,781 |
77,411,150 |
RGD:6480464 |
CTD |
| G |
S100a6 |
S100 calcium binding protein A6 |
|
multiple interactions |
ISO |
2 |
182,895,080 |
182,896,305 |
RGD:6480464 |
CTD |
| G |
S100a8 |
S100 calcium binding protein A8 |
|
multiple interactions |
ISO |
2 |
182,961,994 |
182,962,513 |
RGD:6480464 |
CTD |
| G |
Serpinf1 |
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 |
|
multiple interactions |
ISO |
10 |
62,713,441 |
62,739,444 |
RGD:6480464 |
CTD |
| G |
Sfn |
stratifin |
|
decreases expression |
ISO |
5 |
151,475,395 |
151,479,996 |
RGD:6480464 |
CTD |
| G |
Slc10a3 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 3 |
|
multiple interactions |
ISO |
X |
160,234,831 |
160,238,637 |
RGD:6480464 |
CTD |
| G |
Snai2 |
snail family zinc finger 2 |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Stfa2l1 |
stefin A2-like 1 |
|
multiple interactions |
ISO |
11 |
66,263,202 |
66,267,857 |
RGD:6480464 |
CTD |
| G |
Synpo |
synaptopodin |
|
multiple interactions |
ISO |
18 |
56,552,991 |
56,573,981 |
RGD:6480464 |
CTD |
| G |
Tek |
TEK tyrosine kinase, endothelial |
|
multiple interactions |
ISO |
5 |
115,047,195 |
115,196,172 |
RGD:6480464 |
CTD |
| G |
Tert |
telomerase reverse transcriptase |
|
decreases expression |
ISO |
1 |
30,445,180 |
30,465,942 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
decreases response to substance |
ISO |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
multiple interactions |
ISO |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
multiple interactions |
ISO |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
multiple interactions |
ISO |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
|
decreases expression |
ISO |
5 |
163,666,541 |
163,697,484 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
affects response to substance |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Trim23 |
tripartite motif-containing 23 |
|
multiple interactions |
ISO |
2 |
35,101,019 |
35,135,028 |
RGD:6480464 |
CTD |
| G |
Tyms |
thymidylate synthetase |
|
decreases expression |
ISO |
9 |
112,604,912 |
112,617,706 |
RGD:6480464 |
CTD |
| G |
Tyms |
thymidylate synthetase |
|
multiple interactions |
ISO |
9 |
112,604,912 |
112,617,706 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
|
affects response to substance |
ISO |
1 |
79,834,167 |
79,860,300 |
RGD:6480464 |
CTD |
| G |
Zc3h3 |
zinc finger CCCH type containing 3 |
|
multiple interactions |
ISO |
7 |
113,714,123 |
113,813,124 |
RGD:6480464 |
CTD |
| G |
Zfp35 |
zinc finger protein 35 |
|
multiple interactions |
ISO |
18 |
15,749,584 |
15,765,238 |
RGD:6480464 |
CTD |
Term paths to the root
|